stockportfolio.pro
Stocks / DVA vs JAZZ
DVA vs JAZZ
DaVita Inc. and Jazz Pharmaceuticals plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| DaVita Inc. (DVA) | Jazz Pharmaceuticals plc (JAZZ) | |
|---|---|---|
| Market cap | $13.5B | $14.4B |
| Revenue (latest FY) | $13.64B | $4.27B |
| Net income (latest FY) | $746.80M | $-356.15M |
| Revenue growth (5y CAGR) | 3.4% | 12.5% |
| Net margin | 5.5% | -8.3% |
| Return on equity | -114.7% | -8.2% |
| P/E ratio | 20.2 | 2080.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DVA — free Open JAZZ — freeFrequently asked questions
Which is bigger, DVA or JAZZ?
Jazz Pharmaceuticals plc is larger by market capitalization — $14.4B versus $13.5B.
Which grows faster, DVA or JAZZ?
Over the last five fiscal years, Jazz Pharmaceuticals plc grew revenue faster — 12.5%/yr versus 3.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.